Rapid health technology assessment of brentuximab vedotin for the treatment of relapsed or refractory Hodgkin lymphoma

Category Systematic review
JournalChin. J. New Drugs
Year 2025
This article has no abstract
Epistemonikos ID: de32e699e41c451f1537afee07706f90c3e2ec71
First added on: Oct 15, 2025